194 related articles for article (PubMed ID: 21677985)
1. Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.
Jourden JL; Daniel KB; Cohen SM
Chem Commun (Camb); 2011 Jul; 47(28):7968-70. PubMed ID: 21677985
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic activation of a matrix metalloproteinase inhibitor.
Major Jourden JL; Cohen SM
Chem Commun (Camb); 2010 Feb; 46(8):1241-3. PubMed ID: 20449263
[TBL] [Abstract][Full Text] [Related]
3. A comparative docking study and the design of potentially selective MMP inhibitors.
Hanessian S; Moitessier N; Therrien E
J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074
[TBL] [Abstract][Full Text] [Related]
4. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
5. Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide.
Daniel KB; Major Jourden JL; Negoescu KE; Cohen SM
J Biol Inorg Chem; 2011 Feb; 16(2):313-23. PubMed ID: 21049301
[TBL] [Abstract][Full Text] [Related]
6. Intra- and interdomain flexibility in matrix metalloproteinases: functional aspects and drug design.
Bertini I; Fragai M; Luchinat C
Curr Pharm Des; 2009; 15(31):3592-605. PubMed ID: 19925414
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships.
Gupta SP
Exp Suppl; 2012; 103():v-vi. PubMed ID: 22642187
[No Abstract] [Full Text] [Related]
8. Role of sulfonamide group in matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):368-73. PubMed ID: 18288991
[TBL] [Abstract][Full Text] [Related]
9. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
[No Abstract] [Full Text] [Related]
10. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
11. Quest for selectivity in inhibition of matrix metalloproteinases.
Brown S; Meroueh SO; Fridman R; Mobashery S
Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Yan YL; Miller MT; Cao Y; Cohen SM
Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases.
Fridman R
Biochim Biophys Acta; 2010 Jan; 1803(1):1-2. PubMed ID: 20159302
[No Abstract] [Full Text] [Related]
14. Structural studies of matrix metalloproteinases.
Borkakoti N
J Mol Med (Berl); 2000; 78(5):261-8. PubMed ID: 10954198
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms.
Li X; Li J
Mini Rev Med Chem; 2010 Aug; 10(9):794-805. PubMed ID: 20482497
[TBL] [Abstract][Full Text] [Related]
16. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
Farkas E; Katz Y; Bhusare S; Reich R; Röschenthaler GV; Königsmann M; Breuer E
J Biol Inorg Chem; 2004 Apr; 9(3):307-15. PubMed ID: 14762707
[TBL] [Abstract][Full Text] [Related]
17. From sensors to silencers: quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteases.
Rouffet M; de Oliveira CA; Udi Y; Agrawal A; Sagi I; McCammon JA; Cohen SM
J Am Chem Soc; 2010 Jun; 132(24):8232-3. PubMed ID: 20507095
[TBL] [Abstract][Full Text] [Related]
18. Analysis of matrix degradation.
Munshi HG; Stack MS
Methods Cell Biol; 2002; 69():195-205. PubMed ID: 12070993
[No Abstract] [Full Text] [Related]
19. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
20. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction.
Hu X; Shelver WH
J Mol Graph Model; 2003 Nov; 22(2):115-26. PubMed ID: 12932782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
